New breathing device for newborns tested against standard care

NCT ID NCT02030691

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two non-invasive breathing machines in 49 newborns (born at 33 weeks or later) with respiratory distress. One machine is the standard nasal CPAP, and the other is a newer device called nasal high frequency percussive ventilation. Researchers measured brain oxygen levels to see which device babies tolerated better. The goal was to see if the newer device could be a good alternative.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Nasal continuous positive airway pressure (nCPAP) and nasal high frequency percussive ventilation (nHFPV) devices
What this could lead to
If successful, this could show that a newer breathing device is as well-tolerated as the standard one, potentially offering another option for supporting newborns with breathing problems.
What could go wrong
This is a small, completed study with only 49 babies, so results may not apply to all newborns. It compares tolerance, not long-term outcomes, so it won't tell us which device is better for overall health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEONATAL RESPIRATORY DISTRESS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Service de Néonatalogie - Maternité - Hôpital Pellegrin

    Bordeaux, Bordeaux, 33076, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.